Profile data is unavailable for this security.
About the company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
- Revenue in DKK (TTM)17.76bn
- Net income in DKK5.45bn
- Incorporated1998
- Employees2.29k
- LocationGenmab A/SKalvebod Brygge 43KOEBENHAVN V 1560DenmarkDNK
- Phone+45 70202728
- Fax+45 70202729
- Websitehttps://www.genmab.com/
Mergers & acquisitions
| Acquired company | GMAB:CPH since announced | Transaction value |
|---|---|---|
| ProfoundBio US Co | -2.49% | 1.80bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 13.62bn | 2.36bn | 67.03bn | 5.97k | 28.88 | 2.56 | 17.70 | 4.92 | 1.42 | 1.42 | 8.16 | 15.97 | 0.3169 | 1.93 | 5.38 | 305,843.50 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Ipsen SA | 24.67bn | 4.60bn | 74.98bn | 5.33k | 16.22 | 2.59 | 10.49 | 3.04 | 7.39 | 7.72 | 39.66 | 46.25 | 0.554 | 1.99 | 5.23 | 620,920.20 | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.089 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Recordati Industria Chmc Frmctc SpA | 15.96bn | 2.90bn | 79.26bn | 4.46k | 27.01 | 5.76 | 19.67 | 4.97 | 1.88 | 1.88 | 10.35 | 8.82 | 0.5177 | 1.67 | 4.53 | 480,087.10 | 9.41 | 11.67 | 12.13 | 15.02 | 67.82 | 70.43 | 18.18 | 21.45 | 0.9518 | 7.21 | 0.4883 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Eurofins Scientific SE | 48.60bn | 3.85bn | 83.02bn | 61.80k | 22.09 | 2.18 | 9.82 | 1.71 | 2.61 | 1.30 | 32.92 | 26.44 | 0.6213 | 36.20 | 4.79 | 105,417.60 | 5.41 | 7.49 | 6.70 | 9.36 | 20.93 | 23.78 | 8.71 | 11.23 | 1.38 | 8.43 | 0.4332 | 19.28 | -2.94 | 11.49 | -21.53 | 10.91 | 8.58 | 11.66 |
| BioMerieux SA | 27.42bn | 2.67bn | 87.69bn | 14.65k | 33.00 | 3.13 | 19.07 | 3.20 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sandoz Group AG | -757.61bn | -757.61bn | 106.34bn | 23.85k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Genmab A/S | 17.76bn | 5.45bn | 132.44bn | 2.29k | 24.19 | 4.02 | -- | 7.46 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| argenx SE | 9.76bn | -2.27bn | 154.43bn | 1.15k | -- | -- | -- | 15.83 | -5.26 | -5.26 | 22.57 | -- | -- | -- | -- | 1,139,041.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| UCB SA | 39.18bn | 2.56bn | 178.49bn | 9.08k | 69.87 | 2.60 | 23.14 | 4.56 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2530 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 29 Dec 2023 | 3.24m | 4.90% |
| Schroder Investment Management Ltd.as of 29 Feb 2024 | 2.62m | 3.97% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.32m | 3.51% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.63m | 2.46% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.25m | 1.89% |
| BlackRock Fund Advisorsas of 30 Apr 2024 | 1.14m | 1.72% |
| Baillie Gifford & Co.as of 30 Apr 2024 | 924.42k | 1.40% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 793.83k | 1.20% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 675.62k | 1.02% |
| Harding Loevner LPas of 31 Mar 2024 | 674.62k | 1.02% |
